Objective To determine the expression profiles of miR1301 in the papillary thyroid cancer tissues and analyze its clinical relevance and discuss the possibility of miR1301 as a biomarker for PTC diagnosis. Methods From June 2015 to June 2016, 65 patients of thyroid papillary carcinoma and paracancerous normal thyroid tissues were collected from thyroid surgery in our hospital, including 35 benign cases and 30 papillary carcinoma tissues. miR1301 and miR-1976 from TCGA were validated by qRT-PCR. By online database Targetscan and GEPIA, the target genes of miR-1301 in the PTC were estimated. Results qRT-PCR performed to determine the expression profiles of miR-1301 was down regulated in the papillary thyroid cancer tissues. miR-1976 was no significant difference among paraneoplastic tissue, benign tumor tissue and papillary thyroid cancer tissues. Analyzing clinic features found miR1301 expression levels association with PTC’s “T” and “N” stages. ROC curve indicated miR1301may act as a potential diagnostic marker for PTC, and AUC was 0.774. With bioinformatic analysis, we speculated that miR-1301may participate in PTC growth, apoptosis, migration and metastasis by targeting CLDN1 and TRPC5. In conclusion, we revealed that miR1301 was Downregulated in the PTC tissues and we speculated that serve as a antioncogene by targeting CLDN1 and TRPC5. Conclusion miR-1301 may act as a biomarkers for PTC’s diagnosis, preoperative assessment and prognostic analysis.